Literature DB >> 19514512

[Pathophysiology of restless legs syndrome].

Masayuki Miyamoto1, Tomoyuki Miyamoto, Masaoki Iwanami, Keisuke Suzuki, Koichi Hirata.   

Abstract

Restless legs syndrome (RLS) is a sensorimotor disorder that is frequently associated with periodic leg movements (PLMS). RLS is generally considered to be a central nervous system (CNS)-related disorder although no specific lesion has been found to be associated with the syndrome. Reduced intracortical inhibition has been demonstrated in RLS by transcranial magnetic stimulation. Some MRI studies have revealed the presence of morphologic changes in the somatosensory cortex, motor cortex and thalamic gray matter. The results of SPECT and PET studies showed that the limbic and opioid systems also play important roles in the pathophysiology of RLS. A functional MRI study revealed abnormal bilateral cerebellar and thalamic activation during the manifestation of sensory symptoms, with additional red nucleus and reticular formation activity during PLMS. PLMS is likely to occur in patients with spinal cord lesions, and some patients with sensory polyneuropathy may exhibit RLS symptoms. RLS symptoms seem to depend on abnormal spinal sensorimotor integration at the spinal cord level and abnormal central somatosensory processing. PLMS appears to depend on increased excitability of the spinal cord and a decreased supraspinal inhibitory mechanism from the All diencephalic dopaminergic system. RLS symptoms respond very dramatically to dopaminergic therapy. The results of analysis by PET and SPECT studies of striatal D2 receptor binding in humans are inconclusive. However, studies in animal models suggest that the participation of the All dopaminergic system and the D3 receptor in RLS symptoms. The symptoms of RLS are aggravated in those with iron deficiency, and iron treatment ameliorates the symptoms in some patients. Neuroimaging studies, analysis of the cerebrospinal fluid, and studies on postmortem tissue and use of animal models have indicated that low brain iron concentrations and dysfunction of iron metabolism and intracellular iron may play key roles in the pathogenesis of RLS. The "iron-dopamine model" explains that iron deficiency in the brain causes an abnormality in the dopaminergic system leading to manifestation of RLS. Genetic factors are also important in the development of RLS. A positive family history for RLS has been reported by 40% to 60% of RLS patients. Five loci (RLS 1: 12q, RLS 2: 14q, RLS 3: 9p, RLS 4: 2q, RLS 5: 20p) have been described. Genome-wide association studies have identified variants within the intronic or intergenetic regions of MEIS1 (2p), LBXCOR1/MAP2K5 (15q), BTBD9 (6p), neuronal nitric oxide synthase (NOS1) (12q) and protein tyrosine phosphatase receptor type delta (9p) genes. In conclusion, disturbances in the central dopaminergic system, disturbances in iron metabolism, and genetics seem to be the primary factors in the pathophysiology of RLS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19514512

Source DB:  PubMed          Journal:  Brain Nerve        ISSN: 1881-6096


  4 in total

1.  Challenges in the Treatment of Restless Legs Syndrome: A Case Report.

Authors:  Audrey Umbreit; Shirshendu Sinha; Bhanu Prakash Kolla; Meghna P Mansukhani
Journal:  J Prim Care Community Health       Date:  2021 Jan-Dec

2.  Restless legs syndrome among Saudi end-stage renal disease patients on hemodialysis.

Authors:  Siraj O Wali; Abeer F Alkhouli
Journal:  Saudi Med J       Date:  2015-02       Impact factor: 1.484

3.  Does Dexmedetomidine Improve or Worsen Restless Leg Syndrome under Sedation: A Case Report and Extensive Review.

Authors:  Sandra Iskandar; Marina Souto Martins; Andrew Hudson; Jason G Hirsch; Jonathan S Jahr
Journal:  Case Rep Crit Care       Date:  2022-09-05

4.  Probable rapid eye movement sleep behavior disorder, nocturnal disturbances and quality of life in patients with Parkinson's disease: a case-controlled study using the rapid eye movement sleep behavior disorder screening questionnaire.

Authors:  Keisuke Suzuki; Tomoyuki Miyamoto; Masayuki Miyamoto; Yuka Watanabe; Shiho Suzuki; Muneto Tatsumoto; Masaoki Iwanami; Tsubasa Sada; Taro Kadowaki; Ayaka Numao; Kenichi Hashimoto; Hideki Sakuta; Koichi Hirata
Journal:  BMC Neurol       Date:  2013-02-09       Impact factor: 2.474

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.